Michael DiFiore
Stock Analyst at Evercore ISI
(0.69)
# 3,853
Out of 4,405 analysts
9
Total ratings
44.4%
Success rate
-11.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael DiFiore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $392 → $649 | $480.77 | +34.99% | 2 | May 7, 2026 | |
| VTVT vTv Therapeutics | Initiated Coverage: Buy | $44 | $32.44 | +35.64% | 1 | Mar 12, 2026 | |
| ALT Altimmune | Initiated Coverage: Buy | $25 | $2.61 | +857.85% | 1 | Aug 22, 2025 | |
| SKYE Skye Bioscience | Initiated Coverage: Buy | $10 | $0.7872 | +1,170.33% | 1 | Aug 15, 2025 | |
| HALO Halozyme Therapeutics | Reiterated: Buy | $55 | $69.50 | n/a | 2 | May 15, 2025 | |
| ATRA Atara Biotherapeutics | Downgraded: Hold | n/a | $10.41 | n/a | 1 | Nov 9, 2023 | |
| CLYM Climb Bio | Initiated Coverage: Buy | n/a | $11.44 | n/a | 1 | Sep 8, 2021 |
Madrigal Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: $392 → $649
Current: $480.77
Upside: +34.99%
vTv Therapeutics
Mar 12, 2026
Initiated Coverage: Buy
Price Target: $44
Current: $32.44
Upside: +35.64%
Altimmune
Aug 22, 2025
Initiated Coverage: Buy
Price Target: $25
Current: $2.61
Upside: +857.85%
Skye Bioscience
Aug 15, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $0.7872
Upside: +1,170.33%
Halozyme Therapeutics
May 15, 2025
Reiterated: Buy
Price Target: $55
Current: $69.50
Upside: n/a
Atara Biotherapeutics
Nov 9, 2023
Downgraded: Hold
Price Target: n/a
Current: $10.41
Upside: n/a
Climb Bio
Sep 8, 2021
Initiated Coverage: Buy
Price Target: n/a
Current: $11.44
Upside: n/a